5-HTP

Cheap OTC serotonin precursor that skips the rate-limiting tryptophan hydroxylase (TPH) step and the kynurenine quality-control fork — sounds like a feature, mechanistically a bug. Most of an oral dose is decarboxylated peripherally (gut/blood/kidney) into serotonin where it doesn't help mood/sleep but does drive nausea, GI, and (in chronic high-dose use) theoretical 5-HT2B-mediated cardiac valve risk. For Dylan: skip. L-tryptophan (already in his V5 plan) preserves TPH and IDO gating and is the strictly safer precursor; 5-HTP is only marginally faster onset.

5-HTP is the immediate metabolic intermediate between L-tryptophan and serotonin (5-HT) in the canonical synthesis pathway:

L-Tryptophan → [TPH, rate-limiting] → 5-HTP → [AAAD] → Serotonin (5-HT) → [AANAT, HIOMT, pineal/dark-onset] → Melatonin

Two enzymes matter here:

1. Tryptophan hydroxylase (TPH) — adds the hydroxyl group to tryptophan's indole ring at position 5. This is the rate-limiting step in serotonin synthesis. TPH1 lives in pineal gland and gut enterochromaffin cells; TPH2 lives in CNS serotonergic neurons (raphe nuclei). TPH is regulated: cofactor-dependent (Fe²⁺, BH4, indirectly B6/PLP), substrate-saturable, feedback-modulated by 5-HT levels, and downregulated by stress/inflammation. TPH is your body's quality control on how much serotonin gets made and where.

2. Aromatic amino acid decarboxylase (AAAD, also called DDC) — decarboxylates 5-HTP to serotonin and (separately) L-DOPA to dopamine. AAAD is fast, B6-dependent, and not rate-limiting at physiological substrate concentrations. It's everywhere — gut, liver, kidney, blood, brain — basically any tissue with reasonable B6 levels.

The kynurenine fork. In parallel to the TPH branch, ~95% of dietary tryptophan flows down the kynurenine pathway via IDO (immune cells, brain — induced by inflammation: IL-1, IL-6, IFN-γ, TNF-α) or TDO (mostly liver). This fork produces kynurenic acid (neuroprotective, NMDA antagonist) plus quinolinic acid and 3-hydroxykynurenine (neurotoxic). The IDO/TPH split is itself a quality-control mechanism — when the body is inflamed, it preferentially diverts tryptophan to kynurenines (which have immune-modulatory roles) rather than serotonin.

Why "bypassing TPH" is a bug, not a feature:

• 5-HTP enters the AAAD step directly, skipping both TPH gating (no quality control on serotonin synthesis rate) and the IDO/TDO branch (no diversion to kynurenines). Whatever 5-HTP you swallow becomes serotonin somewhere — the question is just where.
• Most of it becomes serotonin in the wrong tissues. AAAD is far more abundant in the periphery than in the brain. When you take oral 5-HTP, decarboxylation begins in the gut wall, continues in the portal blood and liver, and proceeds in kidney and blood. The fraction reaching the CNS — where you actually want serotonin for mood/sleep effects — is small. (The widely-quoted "CNS:peripheral ~2:90" ratio cited in popular references is approximate but directionally correct: most of an oral 5-HTP dose generates peripheral, not central, 5-HT.) Carbidopa or benserazide (peripheral AAAD inhibitors used in Parkinson's L-DOPA therapy) can boost 5-HTP plasma levels ~14-fold and push more substrate centrally — which tells you exactly how much is normally lost to the periphery.
• Peripheral 5-HT is the wrong product. Gut serotonin → nausea, cramping, diarrhea (the GI side effect signature). Plasma serotonin → platelet uptake → potential cardiovascular signaling. Long-term, sustained peripheral 5-HT is the same biochemical pattern that drives carcinoid syndrome valvulopathy (a neuroendocrine tumor disease where chronic peripheral 5-HT excess causes 5-HT2B-receptor-mediated valve fibrosis). The same pathway was implicated in fenfluramine and pergolide-induced valvular heart disease. Whether this risk applies to chronic moderate-dose 5-HTP supplementation is theoretical and not directly demonstrated in humans, but the receptor mechanism is identical and supports caution at chronic high doses.

Why the LAT1 "advantage" is overstated. Tryptophan crosses the BBB via LAT1 in competition with other large neutral amino acids (LNAAs) — leucine, isoleucine, valine, tyrosine, phenylalanine, methionine. 5-HTP also uses LAT1 but is a less-competed substrate and crosses more readily. Pro-5-HTP framing positions this as 5-HTP's killer feature. The catch: the periphery has its own LAT1-rich tissues (gut, liver) and abundant AAAD, so most 5-HTP is decarboxylated before BBB transit even matters. The BBB advantage is real for the tiny fraction that survives first-pass; for the bulk of the dose it's irrelevant.

Net effect. 5-HTP raises CNS serotonin somewhat (faster than tryptophan because it skips the TPH bottleneck) but also raises peripheral serotonin disproportionately. Tryptophan, by contrast, only raises serotonin where TPH (and adequate cofactors and non-inflamed IDO state) permit — i.e., the body controls where and when serotonin synthesis happens. Tryptophan = regulated precursor. 5-HTP = override switch with peripheral spillover.